Korean news taken with a grain of salt at this point. Prelim indications can certainly be telling but large scale execution is key. No different than a biotech going thru the FDA trial hoops. Lots of time from design to validation to mfg and ultimately sales. Many learning cycles to thumbs up or down the product.

GenPrecis will be ready for select International markets in late 2017 and in the U.S. around May 2018. And it will be a game changer. What is does and the way it does it are spectacular. It should achieve 6% worldwide market share. People will probably trash the package and bash the stock not caring that GenPrecis will be setting a new at-home testing standard. There will be multiple demands for exclusivity -- just like always. But again, what do I know.